Dr. Chakravarthy Garlapati is a molecular and cancer biologist specializing in triple-negative breast cancer (TNBC) and cancer disparities. He earned his Ph.D. from Georgia State University in 2020, focusing on the molecular mechanisms driving TNBC aggressiveness and racial disparities between African American and European American patients. His dissertation, "Evaluation of Novel Druggable Targets and Mechanism of Action in Breast and Prostate Cancer," explored therapeutic targets to address these disparities. Dr. Garlapati’s research investigates metabolic and genetic factors influencing TNBC progression, tumor microenvironment interactions, and novel druggable targets for more effective treatments. His contributions to peer-reviewed publications on TNBC disparities and metabolic rewiring in prostate cancer have advanced the understanding of cancer biology and precision medicine approaches. Beyond academia, he has industry experience in Molecular and Cell Pharmacology and Discovery Biology Research, focusing on drug screening, target validation, and translational oncology. He is also an active member of AACR, SFN, ASCO, SLAS, and IBC. Committed to advancing cancer research, Dr. Garlapati continues to explore innovative therapeutic strategies to bridge gaps in cancer treatment and reduce health disparities.